Medical disclaimer
Information on GLP-1 Samples is provided for general educational and editorial purposes only. It is not medical advice and is not a substitute for professional diagnosis, treatment, or care from a licensed healthcare provider.
Prescription drugs
GLP-1 medications — including but not limited to semaglutide (Ozempic®, Wegovy®, Rybelsus®), tirzepatide (Mounjaro®, Zepbound®), and liraglutide (Saxenda®) — are prescription drugs. They have side effects, contraindications, boxed warnings, and drug interactions. They should only be prescribed by a licensed clinician who has reviewed your medical history and current health status.
Do not use information on this site to start, stop, or change a medication. Always consult your own clinician before any decision related to your health or treatment. If you are experiencing a medical emergency, call 911 immediately.
Off-label prescribing
We describe off-label prescribing of Type 2 diabetes drugs (notably Ozempic and Mounjaro) for weight loss as part of the 2026 access landscape. This is a factual, editorial description of how the market currently operates. Off-label prescribing is a clinical decision made by a licensed clinician working with a specific patient under their professional judgment. We do not recommend, endorse, or facilitate off-label use. Insurance coverage for off-label prescribing is often denied; clinical safety considerations are the same as for the on-label indication; the manufacturer's prescribing information should be consulted by your clinician.
Compounded preparations
We describe compounded semaglutide and compounded tirzepatide programs as part of the cash-pay landscape. Compounded preparations are made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities against individual prescriptions. Compounded preparations are not FDA-reviewed end products and are not equivalent to brand-name Ozempic, Wegovy, Mounjaro, or Zepbound. Their safety, sterility, identity, and potency depend on the practices of the specific compounding pharmacy. The FDA declared semaglutide off the shortage list in early 2025 and tirzepatide in late 2024, narrowing the legal basis for compounding to clinically-justified individual prescriptions. Whether a compounded preparation is appropriate for any specific patient is a clinical decision; we do not prescribe, dispense, or operate any pharmacy ourselves.
No endorsement
We do not endorse any specific provider, clinician, pharmacy, treatment, or manufacturer. Our editorial reviews and rankings reflect our opinions based on public pricing data, manufacturer-published savings card terms, state pharmacy board records, FDA 503B outsourcing facility registrations, and reader-reported offer-status feedback. They are not an endorsement of safety, efficacy, or suitability for any particular individual.
No clinician-patient relationship
Reading this site, contacting us, or interacting with our content does not create a clinician-patient relationship between you and GLP-1 Samples or any contributor. Your relationship with a healthcare provider is established by that provider directly.
Pricing and availability
Pricing, savings card terms, eligibility criteria, and provider availability change frequently. The dates shown next to verification timestamps reflect when we last confirmed the information. Always verify directly with the provider, manufacturer, or pharmacy before relying on a specific number, eligibility threshold, or program rule.
Reach us
If you believe a clinical or editorial statement on the site is inaccurate, email editorial@glp1samples.com. We review and correct factual errors within seven business days.
Last reviewed: 2026-05-02 · GLP1 Samples Editorial Team · Affiliate disclosure · Trademark notice · Terms of service